Industry news that matters to you.  Learn more

N-of-One Selected by Admera Health to Provide Clinical Interpretation for the OncoGxOne 64-Gene Oncology Panel

N-of-One, Inc., the leader in clinical interpretation of molecular tests in oncology, recently announced that Admera Health, a molecular diagnostics company focused on personalized medicine and non-invasive cancer testing, has selected N-of-One to provide clinical interpretation of their 64-gene oncology panel, OncoGxOne™. N-of-One’s patient-specific analysis is based on the clinical and scientific evidence linking the results of each patient’s molecular tests to therapeutic strategies, including clinical trials. Financial terms of the agreement are not disclosed.